Nicox SA

NXOA

Company Profile

  • Business description

    Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.

  • Contact

    Rue Evariste Galois
    Emerald Square, Batiment C
    Sundesk Sophia Antipolis
    Biot06410
    FRA

    T: +33 497245300

    E: [email protected]

    https://www.nicox.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    5

Stocks News & Analysis

stocks

Nvidia earnings: Business as usual as forecasts suggest that all is well

Are the shares cheap?
stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,937.8059.50-0.66%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,689.87191.68-1.76%
HKSE23,263.03245.14-1.04%
NASDAQ24,328.38181.38-0.74%
Nikkei 22559,091.80231.370.39%
NZX 50 Index14,264.2942.67-0.30%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,827.0056.20-0.63%
SSE Composite Index3,574.0310.55-0.29%

Market Movers